
Nutrition & Bronchopulmonary Dysplasia

Camilia R. Martin, MD MS Associate Professor of Pediatrics, Harvard Medical School Associate Director, Neonatal Intensive Care Unit Director for Cross-Disciplinary Research Partnerships, Division of Translational Research Beth Israel Deaconess Medical Center, Boston MA

Disclosures

Scientific Advisor Board: Sancilio, Laurent, Alcresta, Prolacta

Research Funding: Sancilio, Alcresta, Abbott (lipid delivery strategies)




Outline

Epidemiologic Data Demonstrate that Growth Attainment in NICU is Associated with BPD Risk

TABLE 2	Characteristics of Follow-up Cohort by Weight Gain Quartile
---------	---


Variableª	Quartile 1 (<i>n</i> = 124)	Quartile 2 (<i>n</i> = 122)	Quartile 3 (<i>n</i> = 123)	Quartile 4 $(n = 121)$	рь
Weight gain, mean (SD), g/kg per d	12.0 (2.1)	15.6 (0.8)	17.8 (0.8)	21.2 (2.0)	_
BPD, %	56	41	30	31	<.001

Nutrition & BPD: Mechanisms?




- Is nutrition driving the lung disease (A), or is the lung disease driving the nutritional intake (B)
- Role of nutrition:
 - <u>Primary</u> direct evidence of that a specific nutritional parameter or nutrient is in the pathway of lung injury or repair
 - <u>Secondary</u> a proxy to our practices around lung disease (fluid restriction, diuretics, steroids)

Approach to Understand Role of Nutrition in the Prevention and Management of BPD



Preclinical Animal Data Human Cohort Studies Clinical Trials



Total Daily Fluids

Study

Protocol

Cardiopulmonary hemodynamics in lambs during induced capillary leakage immediately after preterm


birth.

Poglase et al. Clin & Exp Pharm & Phys,2011

Preterm lambs, C v Vol Load (50 mL/k), then PEEP challenge

Findings

- Increased protein in BAL fluid
- Interstitial fluid retention
- Decreased PBF, P/SBP, oxygenation
- Increased pulm hemorrhage



Human Cohort Studies

Total Daily Fluids

Study	Protocol	Findings
Hydration during the first <u>4</u> days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. <i>Van Marter, et al. JPeds 1990</i>	Case-Control - n=76/147	 Infants w/ BPD rec'd greater total, crystalloid, and colloid fluids per kilogram per day in the first 4 days of life Greater net weight gain in
200 Crystalloids	200 Crystalloids	the first 4 days of life More likely to be given a clinical diagnosis of patent ductus arteriosus
$A \qquad day of life \\ \leq 1 \text{ kg}$	$B \qquad day of life \\ >1 kg$	

Human Cohort Studies

Total Daily Fluids

Study	Protocol	Findings
Association between fluid intake and weight loss during the first <u>10</u> days of life and risk of BPD in ELBW infants. <i>Oh et al (Neonatal Network),</i> JPeds 2005	Retrospective cohort n=1382	 higher fluid intake and less weight loss during the first 10 days of life associated with an increased risk of BPD

Randomized **Clinical Trials**

Total Daily Fluids


Analysis I.5. Comparison I Restricted versus liberal water intake, Outcome 5 Bronchopulmonary dysplasia.

Review: Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants

Comparison: I Restricted versus liberal water intake

Outcome: 5 Bronchopulmonary dysplasia


Study or subgroup	F	Restricted		Liberal		R	sk Ratio		Weight	Risk Ratio
		n/N		n/N		M-H,Fixe	ed,95% Cl			M-H,Fixed,95% Cl
Bell 1980	751-2000	5/85	122	8/85	169 🔶	•			11.9 %	0.63 [0.21, 1.83]
Kavvadia 2000	<1500	21/84	-11 %	22/84	-	-			32.8 %	0.95 [0.57, 1.60]
Lorenz 1982	750-1500	10/44	65-80	12/44	80-140 ←				17.9 %	0.83 [0.40, 1.73]
Tammela 1992	<1751	21/50	50-120,150	25/50	80-150, 200 -				37.3 %	0.84 [0.55, 1.29]
Total (95% CI)		263		263			-		100.0 %	0.85 [0.63, 1.14]
Total events: 57 (Rest	tricted), 67 (Liberal)								
Heterogeneity: Chi ² :	= 0.5 I, df =	3 (P = 0.92	2); I ² =0.0%	,						
Test for overall effect:	: Z = 1.08 (F	° = 0.28)								
Test for subgroup diff	ferences: No	t applicable	e							
Bell EF, Acarregui MJ:					0.5	0.7 I	1.5	2		in-Pellerin E, Pennaforte T. treatment of preterm infants
intake for preventing infants. Cochrane Dat CD000503			, ,	reterm	Favor	s restrict	Favors libe	eral		isease. Cochrane Database



Energy -Overview

- In experimental models, evaluation of nutritional energy modeled as growth restriction.
 - There remains a high incidence of postnatal growth restriction
 - Growth failure is associated with BPD, including perinatal growth restriction (IUGR)

Restricted Nutrition/Postnatal Growth Restriction




Alveolar formation is dysregulated by restricted nutrition

(Joss-Moore et al, Pediatric Research 2016)

- Lamb
- NIS vs NIS + RN; RN = lower fluids, fat, protein, calories (150 kcal/k/d v 60 kcal/k/d)
- 21 day model
- RN = reduced alveolar count, increased septal wall thickness, decreased caspase-3 (apoptosis), decreased PCNA (proliferation)
- Unable to determine specific nutrient effects; or windows of opportunity/vulnerability

Restricted Nutrition/Postnatal Growth Restriction

- Effect of postnatal malnutrition on hyperoxia-induced newborn lung development (Mataloun et al, Braz J Med Biol Res 2009)
 - New Zealand white rabbits
 - C= control; M= malnutrition (30% reduction in all nutrients); A= room air; H=hyperoxia (95% O₂)
 - 7 day model
 - H = reduced alveolar count; M = enhances hyperoxia effect, Unable to determine specific nutrient effects; or windows of opportunity/vulnerability



Cardiac/Pulmonary Vascular Development

Table 1. Summary of similarities and differences between hyperoxia

 and PNGR in neonatal rat pups

	Hyperoxia	PNGR	Hyperoxia + PNGR
Additive effects		\wedge	
Fulton's index	\uparrow	\uparrow	$\uparrow \uparrow$
RV weight/body weight	Ŷ	Ŷ	$\uparrow \uparrow$
Medial wall thickness	\uparrow	\uparrow	$\uparrow \uparrow$
Vessels per HPF	\downarrow	\downarrow	$\downarrow\downarrow$
BCAA	\downarrow	\downarrow	$\downarrow\downarrow$
Effects unique to hypero	xia		
Mean alveolar area	\uparrow	-	\uparrow
Radial alveolar count	\downarrow	-	\downarrow
Effects similar but not ad	ditive		
VEGF/VEGFR2	\downarrow	\downarrow	\downarrow
HIF1α/HIF2α	\downarrow	\downarrow	\downarrow
P-4E-BP1	\downarrow	\downarrow	\downarrow
eNOS	\downarrow	\downarrow	\downarrow
Nitrate+nitrite	\downarrow	\downarrow	\downarrow

BCAA, branched chain amino acids; eNOS, endothelial nitric oxide synthase; HPF, highpower field; PNGR, postnatal growth restriction; RV, right ventricle.


Restricted Nutrition/Postnatal Growth Restriction

- Postnatal growth restriction augments oxygen-induced pulmonary hypertension
- (Wedgwood et al, Pediatric Research 2016)
 - Rat
 - PNGR induced by increasing litter size
 - 14 day model; Hyperoxia 75% O₂
 - PNGR induces specific mechanistic changes in lung injury –some similar, some additive
 - Unlike previous models, did not play a role in RAC and/or alveolar area
 - Unable to determine specific nutrient effects; or windows of opportunity/vulnerability

Human Cohort Studies

Critical illness in the first weeks of life

Energy Delivery




Later growth and other outcomes

 Early Nutrition Mediates the Influence of Severity of Illness on Extremely Low Birth Weight Infants

(Ehrenkranz et al, Pediatr Res 2011)

- NICHD Neonatal Network
- n=1366
- During the first 7 days of life, the OR of NEC, late-onset sepsis, BPD, and NDI decreased by about 2% for each 1 kcal/ kg/d of total energy intake
- Concept of early energy provision in reducing neonatal morbidities has been reinforced in other cohort studies, including ROP

Randomized Clinical Trials




THE COCHRANE COLLABORATION®

Energy Delivery

• To date, no randomised controlled trials are available that examine the effects of increased versus standard energy intake for preterm infants with (or developing) CLD/BPD.

• Research should be directed at evaluating the effects of various levels of energy intake on this group of infants on clinically important outcomes like mortality, respiratory status, growth and neurodevelopment.

• The benefits and harms of various ways of increasing energy intake, including higher energy density of milk feed and/or fluid volume (clinically realistic target volume should be set), parenteral nutrition, and the use of various constituents of energy like carbohydrate, protein and fat for this purpose also need to be assessed.



Macronutrients – Protein/Fat

 Unable to find any animal or human studies evaluating *total protein* using <u>at</u> <u>least the current recommended dose</u> or *total fat* delivery in neonatal lung injury

 Infants who develop bronchopulmonary dysplasia receive a lower *enteral* intake of calories and total lipids during the first 14 days of life.


dysplasia. Minerva Pediatr 2016;68:419-26.

Building Blocks: Branched chain amino acids and respiratory pattern and function in the neonate. Blazer et al. J Perinat 1992

N=10, Mean gestational age was 30.6 weeks (range 27 to 33 weeks)

BCAA Enriched TPN resulted in:

- Increased dynamic compliance
- Decreased pulmonary resistance
- All values returned to baseline with resumption of the routine TPN




Human Cohort Studies


Base Diet - Breast Milk

- Beyond Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive Human Milk–Based Diet (Hair et al, Breastfeeding Medicine 2016)
 - Multicenter, *retrospective cohort*
 - Pre-, Post- exclusive HUM diet
 - n= 1,587
 - BPD defined as need for oxygen at 36 weeks PMA
 - BOV 56.3% vs HUM 47.7% (p=0.0015)

- Does Breastmilk Influence the Development of BPD? (Spiegler et al, JPeds 2016)
 - Multicenter, *prospective cohort*
 - Exclusive formula vs exclusive breast milk
 - n= 462
 - BPD defined as need for oxygen at 36 weeks PMA + moderate/severe categories as defined by the NIH
 - Formula 20.9% vs BM 11.2% (p=0.005)




Abrupt cessation of in utero nutrient transfer and insufficient postnatal nutritional delivery results in accrued nutrient deficits



Can we identify nutrients important in lung development that can be candidates for targeted delivery in sufficient amounts during critical periods?

Scientific Rationale in Targeted Nutrient Delivery

Poor Postnatal Nutrition Leads to Deficiencies in Important Bioactive Mediators



Benefits of pre-, pro- and Synbiotics for lung angiogenesis in malnutritional rats exposed to intermittent hypoxia.

Ahmad A, Cai CL, Kumar D, et al. Am J Transl Res 2014

- Formula-fed groups were significantly growth suppressed with decreased lung weights
- Lung VEGF was decreased
- All genes involved in angiogenesis were downregulated in the formula-fed groups compared to maternally-fed.

Same effect with delayed feedings!


Preclinical Animal/Human Data

Martin et al. JPeds 2011 Martin et al. Plos One 2014

Late-Onset

Sepsis

Scientific Rationale in **Targeted Nutrient Delivery**



4

Journal of Pediatrics, 2011


0

1

Ь


2 3 Postnatal Week (Birth = Week 0)

RvD1 + LXA4



LOS 40% Hyperoxia

Immunonutrients & CLD



<u>Retinoids</u>

Effect of Retinoic Acid on Oxygen-Induced Lung Injury in the Newborn Rat Ozer et al., Pediatr Pulm, 2005, 39: 35-40

L-Citrulline

L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats.

Vadevel et al., Pediatr Res. 2010 Dec;68(6):519-25.

Vitamin D

Vitamin D treatment improves survival and infant lung structure after intra-amniotic endotoxin exposure in rats: potential role for the prevention of bronchopulmonary dysplasia.

Mandell et al., Am J Physiol Lung Cell Mol Physiol. 2014 Mar 1;306(5):L420-8

Randomized Clinical Trials

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

N Engl J Med 1999;340:1962-8

I VITAMIN A SUPPLEMENTATION FOR EXTREMELY-LOW-BIRTH-WEIGHT INFANTS

JON E. TYSON, M.D., M.P.H., LINDA L. WRIGHT, M.D., WILLIAM OH, M.D., KATHLEEN A. KENNEDY, M.D., LISA MELE, SC.M., RICHARD A. EHRENKRANZ, M.D., BARBARA J. STOLL, M.D., JAMES A. LEMONS, M.D., DAVID K. STEVENSON, M.D., CHARLES R. BAUER, M.D., SHELDON B. KORONES, M.D., AND AVROY A. FANAROFF, M.B., B.CH., FOR THE NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT NEONATAL RESEARCH NETWORK*

Оитсоме	VITAMIN A GROUP (N=405)	CONTROL GROUP (N=402)	Relative Risk (95% CI)*	P VALUE
Chronic lung disease or death by 36 wk post- menstrual age — no. (%)	222 (55)	248 (62)	0.89 (0.80-0.99)	0.03†
Death by 36 wk postmenstrual age — no. (%)	59 (15)	55 (14)	1.07(0.76 - 1.50)	0.72
Death before discharge — no. (%)	67 (17)	66 (16)	$1.01 \ (0.74 - 1.38)$	0.96
Survival with chronic lung disease at 36 wk post- menstrual age — no./total no. (%)	163/346 (47)	193/347 (56)	0.85 (0.73-0.98)	0.03

Randomized Clinical Trials

The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2017;376:1245-55.


ORIGINAL ARTICLE

Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants

Table 2. Primary Outcome and Secondary Respiratory-Related Outcomes.*

Outcome	DHA Group (N = 592)	Control Group (N=613)	Adjusted Effect (95% CI)	Adjusted P Value
Physiological BPD: primary outcome — no. (%)†	291 (49.1)	269 (43.9)	1.13 (1.02–1.25)	0.02
Physiological BPD or death before 36 wk of postmenstrual age — no./total no. (%)†‡	330/631 (52.3)	298/642 (46.4)	1.11 (1.00–1.23)	0.045
Clinical BPD — no./total no. (%)	315/592 (53.2)	304/612 (49.7)	1.09 (1.00–1.18)	0.06
Severity of BPD				
Mild — no. (%)†∬	80 (13.5)	108 (17.6)	0.76 (0.58–0.99)	0.04
Moderate — no. (%)†∬	65 (11.0)	50 (8.1)	1.35 (0.95–1.92)	0.10
Severe — no./total no. (%)¶	202/592 (34.1)	194/612 (31.7)	1.07 (0.93–1.22)	0.36

Successful Bench to Bedside Translation for Targeted Nutrient Delivery



Nutrition Interfaces with the Pathogenesis of BPD

Preclinical/animal data strongly link nutrition with lung development and disease pathogenesis Epidemiology studies and small clinical trials generally supportive (though lots of unknowns) Bedside translation (except Vitamin A) difficult to establish

- Need adequate numbers of infants at highest risk
- What, why, how, & when –; no biomarkers of nutritional efficacy
- Animal models incomplete not fully representative

Recommendations for Nutritional Delivery for the Prevention of BPD

- <u>Total daily fluids</u> an option for care; do not compromise energy delivery and growth
- <u>Energy delivery</u> avoid postnatal growth restriction; don't compromise delivery if fluid restriction imposed (mixed evidence); or other practices that might impact growth attainment (diuretics, steroids). No specific evidence/trials on min/max energy intake and role in BPD pathogenesis
- <u>Macro (total fat/protein)</u> meet minimum requirements, dose to meet energy goals; no BPD data
- <u>Feed the gut</u> gut drives systemic health through modulation of microbiome, innate defenses.
- <u>Base diet</u> human milk; fortification to meet above energy goals; no evidence to preferred fortification strategies
- <u>Immunonutrients</u> Vitamin A; ? Others (not for prime time)

